Financial reports
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
20 Apr 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
6 May 22
10-K
2021 FY
Annual report
10 Mar 22
Current reports
8-K
Regulation FD Disclosure
2 Apr 24
8-K
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
21 Mar 24
8-K
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
26 Feb 24
8-K
Departure of Directors or Certain Officers
7 Feb 24
8-K
Regulation FD Disclosure
11 Dec 23
8-K
Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of
11 Dec 23
8-K
Entry into a Material Definitive Agreement
5 Dec 23
8-K
Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
8-K
Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of
2 Nov 23
8-K
Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce
23 Oct 23
Registration and prospectus
S-8
Registration of securities for employees
21 Mar 24
POS AM
Prospectus update (post-effective amendment)
5 Dec 23
424B5
Prospectus supplement for primary offering
5 Dec 23
S-3
Shelf registration
17 Nov 23
424B5
Prospectus supplement for primary offering
10 Oct 23
424B5
Prospectus supplement for primary offering
14 Jun 23
424B5
Prospectus supplement for primary offering
12 Jun 23
424B5
Prospectus supplement for primary offering
14 Feb 23
424B5
Prospectus supplement for primary offering
25 Jan 23
S-3
Shelf registration
17 Jan 23
Other
EFFECT
Notice of effectiveness
7 Dec 23
EFFECT
Notice of effectiveness
30 Nov 23
UPLOAD
Letter from SEC
27 Nov 23
CORRESP
Correspondence with SEC
27 Nov 23
EFFECT
Notice of effectiveness
25 Jan 23
EFFECT
Notice of effectiveness
25 Jan 23
CORRESP
Correspondence with SEC
20 Jan 23
CORRESP
Correspondence with SEC
20 Jan 23
UPLOAD
Letter from SEC
19 Jan 23
UPLOAD
Letter from SEC
19 Jan 23
Ownership
4
William Richard White
15 Apr 24
4
William Jacob Savage
11 Apr 24
144
Notice of proposed sale of securities
11 Apr 24
4
Kevin Bitterman
7 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
4
Joanne Bryce
1 Mar 24
4
John D Quisel
1 Mar 24
4
Rahul Khara
1 Mar 24
4
Jonathan Yen-Wen Yu
1 Mar 24